A team of Israeli-researchers led by Dr. Regev-Youchay from Sheba Medical Center conducted a 6-month longitudinal prospective study monitoring 4868 health care worker participants from December 2020 through July 2021. Their mission: test the monthly presence of anti-spike IgG and neutralizing bodies as a means of better understanding the durability of the Pfizer-BioNTech mRNA vaccine called BNT162b2. Put another way, how well vaccines actually work overtime is not understood. They found that at six months after receipt of a second dose of the BNT162b2 vaccine, the humoral response declined substantially, with this observation greater among men, the elderly (65+), and among the immunocompromised.
TrialSite provides a brief breakdown of this study. The longitudinal, prospective study timeline indicates that the findings would apply to the wild-type virus and others that may have been present. The study was published in the New England Journal of Medicine.
How many participants?
Participant (Health worker) demographics
Physician 18%; Nurses or nurse aids 27%; Paramedical 21%; Administrative or logistic 34%.
The Real-World Site
Sheba Medical Center, large t...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).